Notice: Get a jump on 2015 — Pay your 2015 ASA membership dues now!




January 23 - 25 2015, 12:00 AM - 12:00 AM


February 07 - 08 2015, 12:00 AM - 12:00 AM

ASA Certificate in Business Administration 2015

June 26 - 28 2015, 12:00 AM - 12:00 AM

Annual Perioperative Surgical Home Summit



December 18, 2014

0.9 Percent Sodium Chloride Injection USP in 100 mL MINI-BAG PLUS Container by Baxter: Recall - Particulate Matter


FDA MedWatch Recall - Particulate Matter

November 21, 2014

FDA MedWatch - Respironics California, Esprit V1000 and V200 Ventilators: Class I Recall - Power Failure May Occur


FDA MedWatch Respironics California Esprit V1000 and V200 Ventilators Class I Recall

November 21, 2014

FDA MedWatch - Highly Concentrated Potassium Chloride Injection, 10 mEq per 100 mL by Baxter: Recall - Mislabeled


Highly Concentrated Potassium Chloride Injection 10 mEq per 100 mL by Baxter Recall Mislabeled



Add this product to your shopping cart

Self-Education and Evaluation (SEE) Program

SKU: 30701-14CE

... Read more »

Single Copies, Member Price: $360

ASA, 31 Others Call for Congressional Action to Combat Drug Shortages

Friday, March 16, 2012

ASA joined 31 other medical organizations in urging House Energy and Commerce Committee Chairman Fred Upton to move forward with legislation to combat the drug shortages crisis.  While acknowledging that drug shortages cannot be solved by Congressional action alone, these organizations suggested legislation be introduced to compliment and strengthen recent regulatory decisions as well as provide new relief measures.

The communication from the drug shortage stakeholders requests that the Committee move forward with legislation that includes: developing an early warning system for production disruption or discontinuation, requiring manufacturers to have contingency plans for raw materials suppliers, encouraging redundancies in manufacturing, requiring collaboration between the Food and Drug Administration (FDA) and Drug Enforcement Agency (DEA) to offer flexibility for product development and raw material quotas and establishing incentives for manufacturers. 

The recommendations are consistent with the findings of the Drug Shortage Summit, a group of stakeholders co-convened by ASA to advance solutions to the drug shortage issue.

Review the full letter.

« Back to Washington Alerts